Back to search results

A Study of ABBV-706 with Atezolizumab for Extensive Stage Small Cell Lung Cancer

This study is for adults with extensive stage small cell lung cancer (SCLC), a fast-growing cancer that can spread quickly. It aims to find the best dose and assess the safety and effectiveness of an investigational drug called ABBV-706, given with atezolizumab. This combination will be compared to the standard treatment (etoposide, carboplatin, and atezolizumab, with optional lurbinectedin). We are looking at how many side effects participants experience (up to 69.5 months) and how long they live without their cancer getting worse (up to about 24 months). You might be able to join if you have newly diagnosed extensive stage SCLC and a good general health status (ECOG Performance Status of 0 to 1). The study plans to enroll about 180 participants worldwide.

Study design
This interventional study will enroll approximately 180 adult participants. Participants will receive either ABBV-706 with atezolizumab at one of two doses, or the standard of care treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events for up to 69.5 months and for progression-free survival for up to approximately 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07155174

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Recruiting
PHASE2Ages 18+InterventionalTreatment
AbbVie
~180 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:ABBV-706AtezolizumabEtoposideCarboplatinLurbinectedin

At a glance

Recruiting sites
67 of 67 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Adverse Events (AE)s
Measured over Up to 69.5 Months
+1 more outcome measured

Conditions

Small Cell Lung Cancer

Explore related trials

Lung Small Cell Carcinoma

Where it's being run

67 sites across 45 states
Turkey (Türkiye)6
Taiwan5
Seoul Teugbyeolsi4
Spain4
Florida3
Shanghai Municipality2
Hesse2
Israel2

Study leadership

  • ABBVIE INC. · STUDY_DIRECTOR · AbbVie

Who to contact

ABBVIE CALL CENTER
[email protected]
844-663-3742
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy.
Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment.
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Suspected brain metastases at screening should have a computed tomography (CT)/ magnetic resonance imaging (MRI) of the brain prior to study entry.

Exclusion

Have received any kind of treatment for limited stage small cell lung cancer (LS-SCLC).
Known active/symptomatic central nervous system (CNS) metastases should be excluded.
History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan should be excluded.
Have any clinically significant conditions that would adversely affect the participant's participation in the study, and the subject should have a life expectancy of at least 3 months.

What this trial measures

  • Number of Participants with Adverse Events (AE)sUp to 69.5 Months

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

  • Progression-Free Survival (PFS) Based on Investigator AssessmentUp to Approximately 24 Months

    PFS is defined as the time from randomization to the first documentation of radiological progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator or death from any cause, whichever occurs first.